Hollie Crutchfield
Nurse Practitioner · Dothan, ALNPI 1891749750
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 63.7% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $12,730, 7.5 times the $1,693 reported in 2021. Among nurse practitioner clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 375 payments — averaging $59.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14K
- AstraZeneca$998
- Amgen$878
- Merck$800
- E.r. Squibb & Sons, L.L.C.$700
- Esperion Therapeutics, Inc.$533
- plus $4K from 27 others
What the payments were for
- Speaking & faculty fees$11,50052%
- Travel & lodging$2,0009%
- Food & beverage$8,74739%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 28 | $14,194 |
| AstraZeneca | 36 | $998 |
| Amgen | 22 | $878 |
| Merck | 52 | $800 |
| E.r. Squibb & Sons, L.L.C. | 34 | $700 |
| Esperion Therapeutics, Inc. | 30 | $533 |
| Novo Nordisk | 10 | $514 |
| Novartis | 34 | $509 |
| Scpharmaceuticals Inc. | 10 | $443 |
| Pfizer | 25 | $397 |
| Lilly USA, LLC | 3 | $275 |
| Boehringer Ingelheim | 17 | $255 |
| Bayer | 10 | $242 |
| Philips North America LLC | 15 | $237 |
| Lexicon Pharmaceuticals, Inc. | 8 | $235 |
| Medtronic | 3 | $164 |
| Cvrx, Inc. | 1 | $137 |
| Johnson & Johnson | 8 | $115 |
| Sanofi-aventis U.S. LLC | 5 | $95 |
| Otsuka America Pharmaceutical, Inc. | 1 | $94 |
| Astellas Pharma US Inc | 1 | $67 |
| Inspire Medical Systems, Inc. | 1 | $59 |
| Kowa Pharmaceuticals America, Inc. | 4 | $58 |
| Boston Scientific | 3 | $56 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Amarin Pharma, Inc. | 3 | $45 |
| Irhythm Technologies, Inc. | 3 | $43 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $20 |
| Abiomed | 1 | $19 |
| Atricure, Inc. | 1 | $17 |
| Inari Medical, Inc. | 1 | $14 |
| Impulse Dynamics (USA) Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,298 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 390 | $379,521 |
| XareltoRivaroxaban | 163 | $160,404 |
| EntrestoSacubitril/Valsartan | 90 | $102,856 |
| Repatha SureclickEvolocumab | 100 | $70,033 |
| FarxigaDapagliflozin Propanediol | 31 | $32,680 |
| VerquvoVericiguat | 21 | $20,100 |
| Ranolazine ErRanolazine | 198 | $19,406 |
| Repatha SyringeEvolocumab | 17 | $15,978 |
| BrilintaTicagrelor | 21 | $13,238 |
| Bisoprolol Fumarate | 357 | $12,610 |
| LivaloPitavastatin Calcium | 15 | $4,831 |
| Nitroglycerin | 377 | $4,171 |
| Nebivolol Hcl | 55 | $3,780 |
| Metoprolol Succinate | 183 | $2,999 |
| ClopidogrelClopidogrel Bisulfate | 264 | $2,955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $397 | $379,521390 claims |
| Johnson & JohnsonXarelto | $115 | $160,404163 claims |
| NovartisEntresto | $509 | $102,85690 claims |
| AstraZenecaFarxiga, Brilinta | $998 | $45,91752 claims |
| MerckVerquvo | $800 | $20,10021 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $58 | $4,83115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Dothan
- Christina BellDothan$14K
- Shea CalhounDothan$14K
- Amanda PybusDothan$13K
- Tami CaldwellDothan$13K
- Alison HallDothan$12K
- Jennifer ParrishDothan$12K
- Amanda SewellDothan$11K
- Amy EthridgeDothan$11K
- Allison McAllisterDothan$10K
- Carol WilliamsDothan$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.